vs
Side-by-side financial comparison of Hologic (HOLX) and Lineage, Inc. (LINE). Click either name above to swap in a different company.
Lineage, Inc. is the larger business by last-quarter revenue ($1.4B vs $1.0B, roughly 1.3× Hologic). Hologic runs the higher net margin — 17.1% vs -7.3%, a 24.4% gap on every dollar of revenue. On growth, Lineage, Inc. posted the faster year-over-year revenue change (3.1% vs 2.5%). Hologic produced more free cash flow last quarter ($215.2M vs $35.0M).
Hologic, Inc. is an American medical technology company primarily focused on women's health; it sells medical devices for diagnostics, surgery, and medical imaging.
Norwegian Cruise Line Holdings (NCLH) is a holding company that is based in the United States and domiciled in Bermuda. It operates three cruise lines as wholly owned subsidiaries: Norwegian Cruise Line, Oceania Cruises, and Regent Seven Seas Cruises. With its subsidiaries combined, it is the third-largest cruise operator in the world. It is a publicly traded company listed on the New York Stock Exchange.
HOLX vs LINE — Head-to-Head
Income Statement — Q1 FY2026 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.0B | $1.4B |
| Net Profit | $179.1M | $-100.0M |
| Gross Margin | 56.0% | 32.3% |
| Operating Margin | 22.6% | 2.5% |
| Net Margin | 17.1% | -7.3% |
| Revenue YoY | 2.5% | 3.1% |
| Net Profit YoY | -10.9% | 79.4% |
| EPS (diluted) | $0.79 | $-0.44 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.0B | — | ||
| Q3 25 | $1.0B | $1.4B | ||
| Q2 25 | $1.0B | $1.4B | ||
| Q1 25 | $1.0B | $1.3B | ||
| Q4 24 | $1.0B | $1.3B | ||
| Q3 24 | $988.0M | $1.3B | ||
| Q2 24 | $1.0B | $1.3B | ||
| Q1 24 | $1.0B | $1.3B |
| Q4 25 | $179.1M | — | ||
| Q3 25 | $187.2M | $-100.0M | ||
| Q2 25 | $194.9M | $-6.0M | ||
| Q1 25 | $-17.4M | $0 | ||
| Q4 24 | $201.0M | $-71.0M | ||
| Q3 24 | $178.6M | $-485.0M | ||
| Q2 24 | $194.5M | $-68.0M | ||
| Q1 24 | $169.9M | $-40.0M |
| Q4 25 | 56.0% | — | ||
| Q3 25 | 55.6% | 32.3% | ||
| Q2 25 | 56.3% | 31.9% | ||
| Q1 25 | 37.5% | 32.2% | ||
| Q4 24 | 56.8% | 32.3% | ||
| Q3 24 | 56.4% | 32.8% | ||
| Q2 24 | 55.4% | 33.4% | ||
| Q1 24 | 53.3% | 33.4% |
| Q4 25 | 22.6% | — | ||
| Q3 25 | 22.6% | 2.5% | ||
| Q2 25 | 24.9% | 1.7% | ||
| Q1 25 | -0.7% | 4.3% | ||
| Q4 24 | 22.5% | -1.6% | ||
| Q3 24 | 23.3% | -38.6% | ||
| Q2 24 | 24.1% | 5.5% | ||
| Q1 24 | 20.7% | 7.6% |
| Q4 25 | 17.1% | — | ||
| Q3 25 | 17.8% | -7.3% | ||
| Q2 25 | 19.0% | -0.4% | ||
| Q1 25 | -1.7% | — | ||
| Q4 24 | 19.7% | -5.3% | ||
| Q3 24 | 18.1% | -36.3% | ||
| Q2 24 | 19.2% | -5.1% | ||
| Q1 24 | 16.7% | -3.0% |
| Q4 25 | $0.79 | — | ||
| Q3 25 | $0.84 | $-0.44 | ||
| Q2 25 | $0.86 | $-0.03 | ||
| Q1 25 | $-0.08 | $0.01 | ||
| Q4 24 | $0.87 | $-0.52 | ||
| Q3 24 | $0.75 | $-2.44 | ||
| Q2 24 | $0.82 | $-0.46 | ||
| Q1 24 | $0.72 | $-0.28 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.4B | — |
| Total DebtLower is stronger | $2.5B | — |
| Stockholders' EquityBook value | $5.2B | $8.4B |
| Total Assets | $9.2B | $19.2B |
| Debt / EquityLower = less leverage | 0.48× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.4B | — | ||
| Q3 25 | $2.2B | — | ||
| Q2 25 | $1.9B | — | ||
| Q1 25 | $1.6B | — | ||
| Q4 24 | $2.0B | $173.0M | ||
| Q3 24 | $2.3B | $409.0M | ||
| Q2 24 | $2.4B | $73.0M | ||
| Q1 24 | $2.2B | — |
| Q4 25 | $2.5B | — | ||
| Q3 25 | $2.5B | — | ||
| Q2 25 | $2.5B | — | ||
| Q1 25 | $2.5B | — | ||
| Q4 24 | $2.5B | — | ||
| Q3 24 | $2.5B | — | ||
| Q2 24 | $2.5B | — | ||
| Q1 24 | $2.6B | — |
| Q4 25 | $5.2B | — | ||
| Q3 25 | $5.0B | $8.4B | ||
| Q2 25 | $4.8B | $8.6B | ||
| Q1 25 | $4.6B | $8.6B | ||
| Q4 24 | $4.8B | $8.6B | ||
| Q3 24 | $5.1B | $9.0B | ||
| Q2 24 | $5.0B | $4.9B | ||
| Q1 24 | $4.8B | $5.6B |
| Q4 25 | $9.2B | — | ||
| Q3 25 | $9.0B | $19.2B | ||
| Q2 25 | $8.8B | $19.4B | ||
| Q1 25 | $8.5B | $18.8B | ||
| Q4 24 | $8.7B | $18.7B | ||
| Q3 24 | $9.2B | $19.3B | ||
| Q2 24 | $8.9B | $18.8B | ||
| Q1 24 | $8.7B | — |
| Q4 25 | 0.48× | — | ||
| Q3 25 | 0.50× | — | ||
| Q2 25 | 0.52× | — | ||
| Q1 25 | 0.55× | — | ||
| Q4 24 | 0.53× | — | ||
| Q3 24 | 0.49× | — | ||
| Q2 24 | 0.51× | — | ||
| Q1 24 | 0.53× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $229.9M | $230.0M |
| Free Cash FlowOCF − Capex | $215.2M | $35.0M |
| FCF MarginFCF / Revenue | 20.5% | 2.5% |
| Capex IntensityCapex / Revenue | 1.4% | 14.2% |
| Cash ConversionOCF / Net Profit | 1.28× | — |
| TTM Free Cash FlowTrailing 4 quarters | $1.0B | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $229.9M | — | ||
| Q3 25 | $355.1M | $230.0M | ||
| Q2 25 | $343.3M | $258.0M | ||
| Q1 25 | $169.4M | $139.0M | ||
| Q4 24 | $189.3M | — | ||
| Q3 24 | $367.0M | $186.0M | ||
| Q2 24 | $405.8M | $155.0M | ||
| Q1 24 | $292.4M | $105.0M |
| Q4 25 | $215.2M | — | ||
| Q3 25 | $341.4M | $35.0M | ||
| Q2 25 | $330.5M | $95.0M | ||
| Q1 25 | $153.9M | $-12.0M | ||
| Q4 24 | $172.5M | — | ||
| Q3 24 | $350.6M | $33.0M | ||
| Q2 24 | $385.3M | $-31.0M | ||
| Q1 24 | $279.6M | $-42.0M |
| Q4 25 | 20.5% | — | ||
| Q3 25 | 32.5% | 2.5% | ||
| Q2 25 | 32.3% | 7.0% | ||
| Q1 25 | 15.3% | -0.9% | ||
| Q4 24 | 16.9% | — | ||
| Q3 24 | 35.5% | 2.5% | ||
| Q2 24 | 38.1% | -2.3% | ||
| Q1 24 | 27.5% | -3.2% |
| Q4 25 | 1.4% | — | ||
| Q3 25 | 1.3% | 14.2% | ||
| Q2 25 | 1.3% | 12.1% | ||
| Q1 25 | 1.5% | 11.7% | ||
| Q4 24 | 1.6% | — | ||
| Q3 24 | 1.7% | 11.5% | ||
| Q2 24 | 2.0% | 13.9% | ||
| Q1 24 | 1.3% | 11.1% |
| Q4 25 | 1.28× | — | ||
| Q3 25 | 1.90× | — | ||
| Q2 25 | 1.76× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.94× | — | ||
| Q3 24 | 2.05× | — | ||
| Q2 24 | 2.09× | — | ||
| Q1 24 | 1.72× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HOLX
| Molecular Diagnostics | $255.3M | 24% |
| Breast Imaging | $219.9M | 21% |
| Services | $216.4M | 21% |
| Capital Equipment Componentsand Software | $187.2M | 18% |
| Cytology Perinatal | $76.0M | 7% |
| Interventional Breast Solutions | $71.2M | 7% |
| Blood Screening | $8.4M | 1% |
| Other Typeof Revenue | $5.4M | 1% |
LINE
| Warehousing Operations | $883.0M | 64% |
| Other | $308.0M | 22% |
| Warehouse Lease | $60.0M | 4% |
| Food Sales | $52.0M | 4% |
| E Commerce And Other | $46.0M | 3% |
| Railcar Lease | $23.0M | 2% |
| Service Other | $5.0M | 0% |
